Extremely low viral reservoir in treated chronically HIV-1-infected individuals
Cristina Gálvez,
Victor Urrea,
Judith Dalmau,
Montse Jimenez,
Bonaventura Clotet,
Valérie Monceaux,
Nicolas Huot,
Lorna Leal,
Victoria González-Soler,
Maria González-Cao,
Michaela Müller-Trutwin,
Asier Sáez-Cirión,
Felipe García,
Julià Blanco,
Javier Martinez-Picado,
Maria Salgado
Affiliations
Cristina Gálvez
IrsiCaixa AIDS Research Institute and Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain; Autonomous University of Barcelona, Cerdanyola del Vallés, Spain
Victor Urrea
IrsiCaixa AIDS Research Institute and Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain
Judith Dalmau
IrsiCaixa AIDS Research Institute and Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain
Montse Jimenez
IrsiCaixa AIDS Research Institute and Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain; Autonomous University of Barcelona, Cerdanyola del Vallés, Spain
Bonaventura Clotet
IrsiCaixa AIDS Research Institute and Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain; Autonomous University of Barcelona, Cerdanyola del Vallés, Spain; ‘Lluita contra la SIDA’ Foundation, Badalona, Spain; University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain
Valérie Monceaux
Institut Pasteur, Unité HIV Inflammation et Persistance, Paris, France
Nicolas Huot
Institut Pasteur, Unité HIV Inflammation et Persistance, Paris, France
Lorna Leal
Infectious Diseases Department, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain
Victoria González-Soler
Centre for Epidemiological Studies on Sexually Transmitted Diseases and HIV/AIDS of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Spain; Microbiology Department. Laboratori Clínic Metropolitana Nord. University Hospital “Germans Trias i Pujol”, Badalona, Spain. Department of Genetics and Microbiology. Autonomous University of Barcelona, Spain; CIBER Epidemiologia y Salud Publica (CIBERESP), Spain
Maria González-Cao
Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital, Barcelona, Spain
Michaela Müller-Trutwin
Institut Pasteur, Unité HIV Inflammation et Persistance, Paris, France
Asier Sáez-Cirión
Institut Pasteur, Unité HIV Inflammation et Persistance, Paris, France
Felipe García
Institut Pasteur, Unité HIV Inflammation et Persistance, Paris, France
Julià Blanco
IrsiCaixa AIDS Research Institute and Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain; University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain
Javier Martinez-Picado
IrsiCaixa AIDS Research Institute and Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain; University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain; Corresponding author at: IrsiCaixa AIDS Research Institute and Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain.
Maria Salgado
IrsiCaixa AIDS Research Institute and Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain; Corresponding author at: IrsiCaixa AIDS Research Institute and Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain
Background: Small viral reservoirs are found predominantly in HIV-1 controllers and individuals treated during acute/early HIV-1 infection. However, other HIV+ individuals could naturally also harbour low viral reservoirs. Methods: We screened 451 HIV-1-infected treated-individuals with suppressed plasma viremia for at least 3 years and stored cryopreserved peripheral blood mononuclear cells (PBMCs). Total HIV-DNA was analysed in PBMCs with ddPCR. Individuals with 50 HIV-DNA copies/106 PBMCs) to analyse total HIV-DNA, T-cell and NK-cell populations, HIV-1 specific antibodies, and plasma inflammation markers. Findings: We found that 9.3% of the individuals screened had <50 HIV-DNA copies/106 PBMCs. At least 66% initiated cART during the chronic phase of HIV-1 infection (cp-LoViReT). Cp-LoViReT harboured lower levels of HIV-DNA before cART and after treatment introduction the decays were greater compared to controls. They displayed a marked decline in quantity and avidity in HIV-specific antibodies after initiation of cART. Cp-LoViReT had fewer CD8+ TTM and TEMRA in the absence of cART, and higher CD8+ TN after 18 months on therapy. Interpretation: Treated chronically HIV-1-infected LoViReT represent a new phenotype of individuals characterized by an intrinsically reduced viral reservoir, less impaired CD8+ T-cell compartment before cART, and low circulating HIV-1 antigens despite being treated in the chronic phase of infection. The identification of this unique group of individuals is of great interest for the design of future eradication studies. Funding: MSD Spain